Biotech Values

[jbog]

I'm very surprised by Revances rapid decline this quarter. It's down around 30% in the quarter and 40% from its quarterly high. This is well beyond anything I expected.
On one side the non-bios have sucked as of late and the market doesn't believe anything until the results are printed, on the other hand I would have to assume they are performing prescriber's data.

Let's hope they're just waiting for the proof.